Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:02 am
Author: Getaka|Social: XLinkedIn

Hester Biosciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹832.24Overvalued by 39.07%vs CMP ₹1,366.00

P/E (28.4) × ROE (9.2%) × BV (₹397.00) × DY (0.51%)

₹572.64Overvalued by 58.08%vs CMP ₹1,366.00
MoS: -138.5% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹839.0822%Over (-38.6%)
Graham NumberEarnings₹655.8216%Over (-52%)
Earnings PowerEarnings₹12.9313%Over (-99.1%)
DCFCash Flow₹309.9213%Over (-77.3%)
Net Asset ValueAssets₹397.347%Over (-70.9%)
EV/EBITDAEnterprise₹862.869%Over (-36.8%)
Earnings YieldEarnings₹481.507%Over (-64.8%)
ROCE CapitalReturns₹927.949%Over (-32.1%)
Revenue MultipleRevenue₹548.405%Over (-59.9%)
Consensus (9 models)₹572.64100%Overvalued
Key Drivers: Wide model spread (₹13–₹928) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.8%

*Investments are subject to market risks

Investment Snapshot

58
Hester Biosciences Ltd scores 58/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health62/100 · Moderate
ROCE 9.7% AverageROE 9.2% AverageD/E 0.37 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 53.7% Stable
Earnings Quality40/100 · Moderate
OPM contracting (23% → 19%) Declining
Quarterly Momentum80/100 · Strong
Revenue (4Q): 2% YoY FlatProfit (4Q): +26% YoY StrongOPM: 23.0% (up 15.0% YoY) Margin expansion
Industry Rank55/100 · Moderate
P/E 28.4 vs industry 53.8 Cheaper than peersROCE 9.7% vs industry 16.4% Below peers3Y sales CAGR: 10% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:02 am

Market Cap 1,162 Cr.
Current Price 1,366
Intrinsic Value₹572.64
High / Low 2,350/1,239
Stock P/E28.4
Book Value 397
Dividend Yield0.51 %
ROCE9.71 %
ROE9.18 %
Face Value 10.0
PEG Ratio34.57

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Hester Biosciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Hester Biosciences Ltd 1,162 Cr. 1,366 2,350/1,23928.4 3970.51 %9.71 %9.18 % 10.0
Venus Remedies Ltd 1,151 Cr. 861 950/28615.1 4450.00 %11.1 %7.16 % 10.0
Lincoln Pharmaceuticals Ltd 1,191 Cr. 595 679/44013.6 3570.30 %17.3 %12.8 % 10.0
Ind-Swift Laboratories Ltd 1,128 Cr. 138 152/67.223.8 1600.00 %0.78 %0.18 % 10.0
TTK Healthcare Ltd 1,107 Cr. 784 1,402/73515.9 7681.28 %9.26 %6.89 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Hester Biosciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 74.9467.3087.8570.4666.9879.2682.2783.6963.2281.9384.1170.9777.42
Expenses 56.1855.6373.4957.2456.8363.3464.6264.5358.1562.7561.3059.2559.62
Operating Profit 18.7611.6714.3613.2210.1515.9217.6519.165.0719.1822.8111.7217.80
OPM % 25.03%17.34%16.35%18.76%15.15%20.09%21.45%22.89%8.02%23.41%27.12%16.51%22.99%
Other Income 6.373.492.525.912.204.632.092.808.78-5.643.3711.881.98
Interest 3.891.372.578.082.196.945.015.89-3.815.621.812.211.82
Depreciation 5.245.375.404.283.753.744.134.204.294.184.184.354.43
Profit before tax 16.008.428.916.776.419.8710.6011.8713.373.7420.1917.0413.53
Tax % 24.00%32.19%24.69%40.18%37.44%35.16%29.34%29.32%14.66%58.82%14.36%15.90%31.19%
Net Profit 12.165.716.714.044.026.407.498.3911.411.5417.2914.339.32
EPS in Rs 13.155.336.904.814.685.827.459.6413.711.5219.3316.9910.31

Last Updated: February 5, 2026, 5:39 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 9:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 6990101123136178183214235266305311314
Expenses 4464678289110128146175215251250243
Operating Profit 24253441476855696051546272
OPM % 36%28%34%33%35%38%30%32%26%19%18%20%23%
Other Income 13103761142015812
Interest 6544477749201311
Depreciation 5667101213131721171717
Profit before tax 13182531365741505440324054
Tax % 31%26%23%26%36%28%25%31%26%30%34%27%
Net Profit 9131923234131353928212942
EPS in Rs 11.1115.9922.5727.6830.1248.8734.2940.4746.2231.3022.2132.3148.15
Dividend Payout % 18%19%18%19%33%23%19%25%22%26%27%22%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)44.44%46.15%21.05%0.00%78.26%-24.39%12.90%11.43%-28.21%-25.00%38.10%
Change in YoY Net Profit Growth (%)0.00%1.71%-25.10%-21.05%78.26%-102.65%37.29%-1.47%-39.63%3.21%63.10%

Hester Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:11%
3 Years:10%
TTM:5%
Compounded Profit Growth
10 Years:9%
5 Years:-1%
3 Years:-11%
TTM:94%
Stock Price CAGR
10 Years:14%
5 Years:6%
3 Years:0%
1 Year:-15%
Return on Equity
10 Years:14%
5 Years:11%
3 Years:9%
Last Year:9%

Last Updated: September 5, 2025, 6:05 am

Balance Sheet

Last Updated: December 4, 2025, 1:21 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 9999999999999
Reserves 667693113132169193220251271283306329
Borrowings 485559666990121110228274244213214
Other Liabilities 192025253532657374116126126124
Total Liabilities 142160186213244299387411562670662653675
Fixed Assets 546065102110145142133237259240233247
CWIP 213336213277410982149171183182
Investments 000000002125303437
Other Assets 68688589102148170169222237221203209
Total Assets 142160186213244299387411562670662653675

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 9201935384737589244865
Cash from Investing Activity + -15-21-13-30-26-21-73-42-117-77-22-20
Cash from Financing Activity + 77-72-11319-1811242-26-52
Net Cash Flow 25-16128-17-23-12-0-7
Free Cash Flow -51551524-3617-87-542444
CFO/OP 79%100%74%102%100%92%86%105%43%63%112%123%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-24.00-30.00-25.00-25.00-22.00-22.00-66.00-41.00-168.00-223.00-190.00-151.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 75729579876711684861099486
Inventory Days 1,145431627376505540834452424399288291
Days Payable 14568109841009326120410114198122
Cash Conversion Cycle 1,074434614371491514690332409367284255
Working Capital Days 367611290821061041341138811274
ROCE %18%15%19%19%20%26%16%18%14%9%9%10%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%
FIIs 0.45%0.45%0.42%0.43%0.43%0.52%0.61%0.59%0.87%0.51%0.53%0.52%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.02%0.02%0.02%0.00%0.01%
Public 45.81%45.82%45.84%45.83%45.84%45.74%45.66%45.65%45.38%45.73%45.73%45.75%
No. of Shareholders 13,12012,98413,34213,45012,84411,30511,53811,47311,85311,81012,26012,603

Shareholding Pattern Chart

No. of Shareholders

Hester Biosciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF 41 0.08 0.01412025-04-22 17:25:330%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 33.8924.8832.9646.4140.79
Diluted EPS (Rs.) 33.8924.8832.9646.4140.79
Cash EPS (Rs.) 48.8239.6552.1065.4156.44
Book Value[Excl.RevalReserv]/Share (Rs.) 369.41356.03339.19314.32277.37
Book Value[Incl.RevalReserv]/Share (Rs.) 369.41356.03339.19314.32277.37
Revenue From Operations / Share (Rs.) 365.70357.99312.79276.25251.95
PBDIT / Share (Rs.) 76.3875.5877.3086.6686.21
PBIT / Share (Rs.) 56.6355.3952.9767.1770.56
PBT / Share (Rs.) 41.7032.1442.0262.3958.90
Net Profit / Share (Rs.) 29.0719.4627.7745.9240.79
NP After MI And SOA / Share (Rs.) 32.3122.2031.3046.4140.47
PBDIT Margin (%) 20.8821.1124.7131.3734.21
PBIT Margin (%) 15.4815.4716.9324.3128.00
PBT Margin (%) 11.408.9713.4322.5823.37
Net Profit Margin (%) 7.945.438.8716.6216.18
NP After MI And SOA Margin (%) 8.836.2010.0016.8016.06
Return on Networth / Equity (%) 8.746.479.5115.1815.08
Return on Capital Employeed (%) 9.128.468.6412.2817.16
Return On Assets (%) 4.202.853.977.028.37
Long Term Debt / Equity (X) 0.420.620.660.630.36
Total Debt / Equity (X) 0.660.810.950.850.37
Asset Turnover Ratio (%) 0.470.450.430.520.62
Current Ratio (X) 1.562.031.532.012.63
Quick Ratio (X) 0.991.310.961.231.62
Inventory Turnover Ratio (X) 4.260.670.660.520.39
Dividend Payout Ratio (NP) (%) 18.5636.0231.9421.5416.30
Dividend Payout Ratio (CP) (%) 11.5218.8617.9715.1711.76
Earning Retention Ratio (%) 81.4463.9868.0678.4683.70
Cash Earning Retention Ratio (%) 88.4881.1482.0384.8388.24
Interest Coverage Ratio (X) 5.123.257.0618.1411.11
Interest Coverage Ratio (Post Tax) (X) 2.951.843.5310.616.76
Enterprise Value (Cr.) 1279.651416.651555.602514.681703.08
EV / Net Operating Revenue (X) 4.114.655.8510.707.95
EV / EBITDA (X) 19.6922.0323.6634.1123.22
MarketCap / Net Operating Revenue (X) 3.433.884.869.837.61
Retention Ratios (%) 81.4363.9768.0578.4583.69
Price / BV (X) 3.394.054.628.887.14
Price / Net Operating Revenue (X) 3.433.884.869.837.61
EarningsYield 0.020.010.020.010.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Hester Biosciences Ltd. is a Public Limited Listed company incorporated on 29/04/1987 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L99999GJ1987PLC022333 and registration number is 022333. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 286.47 Cr. and Equity Capital is Rs. 8.51 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals�Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat 380006Contact not found
Management
NamePosition Held
Dr. Bhupendra GandhiChairman
Mr. Rajiv GandhiManaging Director & CEO
Ms. Priya GandhiExecutive Director
Mr. Ravin GandhiDirector
Mr. Sanjiv GandhiDirector
Mr. Ashok BhadakalIndependent Director
Ms. Sandhya PatelIndependent Director
Mr. Ameet DesaiIndependent Director
Mr. Anil JainIndependent Director
Mr. Jatin TrivediIndependent Director
Ms. Nina GandhiAlternate Director

FAQ

What is the intrinsic value of Hester Biosciences Ltd and is it undervalued?

As of 18 April 2026, Hester Biosciences Ltd's intrinsic value is ₹572.64, which is 58.08% lower than the current market price of ₹1,366.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (9.18 %), book value (₹397), dividend yield (0.51 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Hester Biosciences Ltd?

Hester Biosciences Ltd is trading at ₹1,366.00 as of 18 April 2026, with a FY2026-2027 high of ₹2,350 and low of ₹1,239. The stock is currently near its 52-week low. Market cap stands at ₹1,162 Cr..

How does Hester Biosciences Ltd's P/E ratio compare to its industry?

Hester Biosciences Ltd has a P/E ratio of 28.4, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Hester Biosciences Ltd financially healthy?

Key indicators for Hester Biosciences Ltd: ROCE of 9.71 % is on the lower side compared to the industry average of 16.35%. Dividend yield is 0.51 %.

Is Hester Biosciences Ltd profitable and how is the profit trend?

Hester Biosciences Ltd reported a net profit of ₹29 Cr in Mar 2025 on revenue of ₹311 Cr. Compared to ₹39 Cr in Mar 2022, the net profit shows a declining trend.

Does Hester Biosciences Ltd pay dividends?

Hester Biosciences Ltd has a dividend yield of 0.51 % at the current price of ₹1,366.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Hester Biosciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports